Trends in GLP ‐1 Receptor Agonist Prescribing Without an Apparent FDA ‐Approved Indication
Obesity · 2026
DOI: 10.1002/oby.70301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2026. Verfasst von Babak J Orandi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, New York University, New York, New York, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Practice Patterns, Physicians'. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Objective
This study evaluated temporal trends and patient characteristics associated with glucagon‐like peptide‐1 (GLP‐1) receptor agonist prescribing among US adults without an apparent FDA‐approved indication.
Methods
This retrospective cohort study used Cosmos electronic health records (01/2021–12/2025). Adults prescribed liraglutide, semaglutide, or tirzepatide without a documented indication (type 2 diabetes or obesity with qualifying comorbidities) were included. Patients without a recorded weight ≥ 6 months prior to first prescription were excluded. Demographic and clinical characteristics were compared using t ‐tests and χ 2 tests.
Results
Among 92,415,648 adults without an apparent FDA‐approved indication, 1,133,953 (1.2%) were prescribed GLP‐1 receptor agonists. Prescribing increased from 0.1% in 2021 to 1.5% in 2025 (15‐fold). Recipients had higher median BMI (25.9 vs. 24.5 kg/m 2 ) and were more often female (85.5%) and White (60.0%). Hypertension and dyslipidemia were more common, while coronary artery disease and heart failure were less prevalent. Notably, 35.1% had normal BMI; eating disorders were more frequent (1.8% vs. 0.3%). GLP‐1 receptor agonist use was associated with lower social vulnerability and private insurance.
Conclusions
GLP‐1 receptor agonist prescribing without an apparent FDA‐approved indication has increased rapidly and disproportionately involves socioeconomically advantaged populations, including individuals without obesity. The risk–benefit profile in these populations remains uncertain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, New York University, New York, New York, USA.
- Department of Medicine, New York University, New York, New York, USA.
- Department of Population Health, New York University, New York, New York, USA.
ORCID-Profile: Babak J Orandi, Macey L Levan, Karan R Chhabra, S Ali Husain, Mara A McAdams-DeMarco, Dorry L Segev
Zitieren
APA
Orandi, B. J., Yan, L., Levan, M. L., Lofton, H. F., Chhabra, K. R., Ren-Fielding, C. J., Husain, S. A., McAdams-DeMarco, M. A., Segev, D. L., Mankowski, M. A., & Massie, A. B. (2026). Trends in GLP ‐1 Receptor Agonist Prescribing Without an Apparent FDA ‐Approved Indication. Obesity. https://doi.org/10.1002/oby.70301
Vancouver
Orandi BJ, Yan L, Levan ML, Lofton HF, Chhabra KR, Ren-Fielding CJ, et al. Trends in GLP ‐1 Receptor Agonist Prescribing Without an Apparent FDA ‐Approved Indication. Obesity. 2026. doi:10.1002/oby.70301
BibTeX
@article{Orandi2026,
author = {Orandi, Babak J and Yan, Leila and Levan, Macey L and Lofton, Holly F and Chhabra, Karan R and Ren-Fielding, Christine J and Husain, S Ali and McAdams-DeMarco, Mara A and Segev, Dorry L and Mankowski, Michal A and Massie, Allan B},
title = {Trends in GLP ‐1 Receptor Agonist Prescribing Without an Apparent FDA ‐Approved Indication},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70301}
}
EUVIMED